Trillium Therapeutics Inc.

87 articles about Trillium Therapeutics Inc.

• Trillium Therapeutics Appoints Dr. Ingmar Bruns as Chief Medical Officer

  11/2/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of Ingmar Bruns, M.D., Ph.D. as Chief Medical Officer, effective immediately.

• Trillium Therapeutics Announces Formation of Scientific Advisory Board

  11/2/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the formation of a Scientific Advisory Board (“SAB”), including Karen Ferrante, MD, Gordon Freeman, PhD, Tom Reynolds, MD, PhD, Steven Rosen, MD, and Jeff Settleman, PhD.

• Trillium Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office

  10/5/2020

  Trillium Therapeutics Inc. announced that it has received Notices of Allowance from the United States Patent and Trademark Office for two patent applications covering the use of SIRPaFc for the treatment of cancer, U.S. Patent Application No. 13/320,629 and U.S. Patent Application No. 15/962,540.

• Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of DirectorsIndustry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board

  9/18/2020

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of pharmaceutical industry leader Michael Kamarck, Ph.D., to its Board of Directors, effective immediately.

• Trillium Closes US$150 Million Public Offering of Common Shares

  9/16/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of common shares of the Company at a public offering price of US$13.00 per common share (the “Offering”).

• Trillium Announces Pricing of US$130 Million Public Offering of Common Shares

  9/11/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 10,000,000 common shares (the “Common Shares”) of the Company (the “Offering”).

• Trillium Announces Proposed Public Offering of Common Shares

  9/9/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of up to 8,500,000 common shares (the “Common Shares”) of the Company (the “Offering”)

• Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies

  9/8/2020

  TTI-622 (SIRPa-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymphoma; now escalating to 12 mg/kg dose level.

• Trillium Therapeutics Announces $25 Million Equity Investment From Pfizer Inc.

  9/8/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has agreed to sell 2,297,794 of its common shares at a price of $10.88 per share to Pfizer Inc. (NYSE: PFE), for gross proceeds of $25.0 million (the “Transaction”). 

• Trillium Therapeutics Reports Second Quarter 2020 Financial and Operating Results

  8/12/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the six months ended June 30, 2020.

• Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level

  7/30/2020

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, provided an update on its ongoing phase 1b dose optimization study of TTI-621 in patients with relapsed and/or refractory cutaneous T-cell lymphoma.

• Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

  7/6/2020

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders held on June 30, 2020.

• Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program

  5/29/2020

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced data from an ongoing phase 1 dose escalation study of TTI-622 in patients with advanced relapsed or refractory lymphoma.

• Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results

  5/15/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2020.

• Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

  5/13/2020

  Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its novel CD47 checkpoint inhibitor, TTI-622, at the Developmental Therapeutics Session of the ASCO20 Virtual Scientific Program to be held May 29-31, 2020. The presentation will highlight a first-in-human study evaluating TTI-622 in patients wi

• Trillium Therapeutics Announces “At-The-Market” Equity Program

  5/6/2020

  Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced that it has established an at-the-market equity program.

• Trillium Therapeutics Provides Business Update In Response To The Covid-19 Pandemic

  4/8/2020

  “During this unprecedented time in recent history, Trillium is working hard to ensure operational continuity to serve patients whose lives are affected by severe diseases while protecting the health of our employees,” said Jan Skvarka, President and Chief Executive Officer of Trillium.

• Trillium Therapeutics Reports Annual Financial and Operating Results

  3/10/2020

  Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including an update on its transformation program, for the year ended December 31, 2019.

• Research Studies Progressing Towards New FDA Approved Treatments for Glioblastoma

  3/3/2020

  Although there is presently no cure for glioblastoma, researchers are continually inching closer to new and effective treatment options.

• Trillium Therapeutics Responds to Market Activity

  2/28/2020

  At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. (the “Company”) (NASDAQ/TSX: TRIL) wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its common shares.